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It is unclear which treatment should be given after stopping teriparatide therapy for
severe osteoporosis. In a prospective, randomized, controlled, 2-yr study, we
compared BMD effects and clinical safety of three follow-up treatments (anabolic
with teriparatide, antiresorptive with raloxifene, or no active treatment) after 1 yr of
teriparatide. Postmenopausal women with osteoporosis and a recent fragility
fracture received open-label teriparatide (20 microg/d) for 12 mo before they were
randomized (3:1:1) to continue teriparatide (n = 305), switch to raloxifene 60 mg/d
(n = 100), or receive no active treatment for the second year (n = 102). All patients
received calcium and vitamin D supplementation. Changes in areal BMD from
baseline to 24 mo were analyzed using mixed-model repeated measures. Daily
teriparatide treatment for 2 yr significantly increased spine BMD by 10.7%. Patients
receiving raloxifene in year 2 had no further change in spine BMD from year 1
(change from baseline, 7.9%), whereas patients receiving no active treatment had a
BMD decrease of 2.5% in year 2 (change from baseline, +3.8%). At the total hip,
BMD increases from baseline at 2 yr were 2.5% with teriparatide, 2.3% with
raloxifene, and 0.5% with no active treatment; the respective changes at the femoral
neck were 3.5%, 3.1%, and 1.3%. The study had insufficient power to assess
antifracture efficacy. In conclusion, BMD increases progressively over 2 yr of
teriparatide therapy in women with severe osteoporosis. After discontinuation of
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